Volume: 40, Article ID: e2018049, 9 pages https://doi.org/10.4178/epih.e2018049

ORIGINAL ARTICLE



Association of appendicular skeletal muscle mass with carotid intima-media thickness according to body mass index in Korean adults

Ji Eun Heo^{1,2}, Hyeon Chang Kim^{2,3}, Jee-Seon Shim^{2,3}, Bo Mi Song², Hye Yoon Bae², Ho Jae Lee², Il Suh³

¹Department of Public Health, Yonsei University Graduate School, Seoul, Korea; ²Cardiovascular and Metabolic Disease Etiology Research Center, Yonsei University College of Medicine, Seoul, Korea; ³Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea

OBJECTIVES: The combined effects of obesity and appendicular skeletal muscle (ASM) on atherosclerosis, especially in middleaged populations, remain poorly understood. This cross-sectional study investigated the effects of ASM on carotid intima-media thickness (IMT) according to body mass index (BMI) in middle-aged Korean adults.

METHODS: Herein, 595 men and 1,274 women aged 30-64 years completed questionnaires and underwent health examinations as part of the Cardiovascular and Metabolic Disease Etiology Research Center cohort. ASM was measured via bioelectrical impedance analysis and adjusted for weight (ASM/Wt). IMT was assessed using B-mode ultrasonography; highest quartile of IMT was defined as gender-specific top quartile of the IMT values. Higher BMIs was defined as a BMI over 25.0 kg/m².

RESULTS: Compared to the highest ASM/Wt quartile, the lowest ASM/Wt quartile was significantly associated with highest quartile of IMT in men with lower BMIs (adjusted odds ratio [aOR], 2.78; 95% confidence interval [CI], 1.09 to 7.13), but not in those with higher BMIs (aOR, 0.59; 95% CI, 0.24 to 1.91). In women, there was no significant association of low skeletal muscle mass with highest quartile of IMT, regardless of BMI.

CONCLUSIONS: Low appendicular skeletal muscle mass is associated with carotid arterial wall thickening in men with lower BMIs, but not in men with higher BMIs. Our findings suggest that the risk of atherosclerosis may be low in middle-aged Korean men with appropriate body weight and skeletal muscle mass maintenance.

KEY WORDS: Sarcopenia, Muscles, Skeletal, Body mass index, Body composition, Atherosclerosis

INTRODUCTION

Although obesity is a major modifiable risk factor for cardiovascular disease (CVD), the mechanisms linking obesity and ath-

Correspondence: Hyeon Chang Kim

Department of Preventive Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea E-mail: hckim@yuhs.ac

Received: Jul 5, 2018 / Accepted: Oct 7, 2018 / Published: Oct 7, 2018

This article is available from: http://e-epih.org/

© This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

© 2018, Korean Society of Epidemiology

erosclerosis are not fully understood. Sarcopenia, an age-related decline in skeletal muscle mass, leads to metabolic and vascular abnormalities [1,2]. Previous epidemiologic studies of the combined effects of low muscle mass and obesity on cardiometabolic disorders have yielded inconsistent results [3-8]. Moreover, most of these studies screened for the presence of a synergistic relationship between muscle mass and body mass index (BMI) in older adults. Little information is available regarding the independent relationship between skeletal muscle mass and atherosclerosis in the middle-aged population. Furthermore, few studies have investigated whether associations between skeletal muscle mass and arterial wall thickness may vary according to obesity categories. The purpose of this study was to evaluate the association of skeletal muscle mass with 2 markers of atherosclerosis—a higher carotid intima-media thickness (IMT) and carotid artery plaque—in a

middle-aged Korean population stratified by BMI categories.

MATERIALS AND METHODS

Study population

The present study used data from the Cardiovascular and Metabolic Disease Etiology Research Center cohort study, which was designed to recruit members of the general population residing in 4 districts (Seoul, Goyang, Gimpo, and Incheon) in South Korea (hereafter Korea). The eligibility criteria for inclusion were being aged 30 to 64 years, having lived for more than 8 months of the year at the current residence with no plans to move over the next 2 years, and having the ability to provide verbal or written consent to participate in the study. Participants were excluded if they had been diagnosed with cancer within the last 2 years or were currently being treated for cancer; had a history of myocardial infarction, stroke, or heart failure; were currently involved in pharmaceutical trials; or were currently pregnant or reported the possibility of being pregnant on the day of registration. The sampling and measurement procedures have been described in detail previously [9]. This study initially enrolled 2,465 participants aged 30-64 years between 2013 and 2015. All participants completed health questionnaires and examinations according to a predefined protocol. People aged <40 years (n = 551), those with missing key variables (n = 14), and those with a BMI under 18.5 kg/m² (n = 31) were excluded from the current analyses. Finally, a cross-sectional analysis of the remaining 595 men and 1,274 women was conducted. All participants provided written informed consent, and the study protocol was approved by the institutional review board hospital at Yonsei University College of Medicine (4-2013-0661).

Questionnaire data

All participants were individually interviewed using standardized questionnaires to obtain information regarding demographics, medication use, and lifestyle behaviors. Trained interviewers conducted face-to-face interviews and questionnaire surveys according to the protocol. Three groups were stratified by smoking status: current smokers, former smokers, and non-smokers. Similarly, participants were classified as current regular alcohol drinkers, former drinkers, or non-drinkers. Physical activity was assessed using the International Physical Activity Questionnaire-Short Form. Regular exercise was defined as moderate- to highintensity physical activity performed at least 3 times per week.

Physical examination

Standing height was measured to the nearest 0.1 cm using a stadiometer (DS-102, Dong Sahn Jenix, Seoul, Korea), and body weight was measured to the nearest 0.1 kg on a digital scale (DB-150, CAS, Seongnam, Korea) according to the predetermined protocol. BMI was calculated as the body weight divided by the standing height squared (kg/m²). Waist circumference was assessed to the nearest 0.1 cm at the midpoint between the lower border of the rib cage and the iliac crest using an ergonomic circumference-

Laboratory assays

Blood samples were collected from the antecubital vein after the patients had fasted for at least 8 hours. Total cholesterol (TC), high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol, and triglyceride levels were measured via enzymatic methods (Advia 1800 autoanalyzer, Siemens Medical Solutions, Deerfield, IL, USA). The TC to HDLC ratio (TC/HDLC) was calculated to evaluate dyslipidemia. Fasting blood glucose concentrations were measured using a colorimetric method (Advia 1800 autoanalyzer, Siemens Medical Solutions), and hemoglobin A1c (HbA1c) concentrations were assessed via high-performance liquid chromatography (Variant II Turbo, Bio-Rad, Berkeley, CA, USA) according to the National Glycohemoglobin Standardization Program guidelines. C-reactive protein concentrations were determined using a turbidimetric immunoassay (Advia 1800 autoanalyzer, Siemens Medical Solutions).

Measurement of skeletal muscle mass

Appendicular skeletal muscle mass (ASM) was measured via bioelectrical impedance analysis (BIA) using Inbody370 (Biospace, Seoul, Korea) according to the instructions provided by the manufacturer. ASM was determined as the sum of the lean muscle masses of both arms and both legs. As the absolute amount of skeletal muscle is known to correlate strongly with body size, ASM is commonly adjusted using indicators of body size such as the height squared, weight, or BMI. In this study, we used weight-adjusted ASM (ASM/Wt) because previous studies reported that this parameter correlated better with cardiometabolic risk factors than did height squared- or BMI-adjusted ASM [10,11]. Participants were divided into 4 groups based on gender-specific ASM/Wt quartiles: <30.85, 30.85-32.36, 32.37-33.87, and \geq 33.88% for men and <25.84, 25.84-27.31, 27.32-28.90, and \geq 28.91% for women.

Measurement of arterial wall thickness

The bilateral common carotid arteries were assessed via Bmode ultrasonography with an 8-MHz linear probe (Accuvix XG, Samsung Medison, Seoul, Korea) according to a predetermined protocol. Participants were placed in the supine position with the head turned at a 30° angle contralateral to the scanning side. Subsequently, the IMT was measured bilaterally in the 1-cm segment proximal to the carotid bulb dilatation and calculated as the mean value of the right and left common carotid arteries from computer-based measurement points in the region. The highest quartile of IMT was defined as the gender-specific top quartile of the mean IMT value (≥ 0.755 mm for men and ≥ 0.724 mm for women). Carotid artery plaque was defined as a focal thickening

| Vindlet Montheral (1) Montheral (1)< | Quartiles of | Quartiles of ASM/Wt | | | | | |
|--|-----------------------|----------------------|-------------------------|---------------------|---------------------|----------------------------------|-----------------------------|
| Q1 Q2 Q3 Q3 Q4 | | | Women (n=1,274) | 1,274) | | | |
| Age (v) 550±66 550±66 550±66 550±66 550±66 550±66 550±66 550±66 550±66 550±66 550±66 550±66 550±66 550±66 550±64 60001 153±26 60001 550±16 550±66 550±65 551±210 71004±51 0001 60011 553±20 60001 553±20 60001 553±20 60001 553±20 60001 552±23 552±20 50001 553±26 652±26 552±20 60001 553±26 652±25 854±51 753±85 552±23 70013 60011 553±26 60011 553±26 60011 553±26 652±25 80±451 753±26 652±25 80±451 753±85 655±132 70011 70011 753±85 753±85 753±85 753±85 753±85 753±85 753±85 753±85 753±61 753±85 753±85 753±85 753±85 753±85 753±85 753±85 753±85 753±85 753±85 753±85 753±86 753±86 753±86 | | | Q2 (25.84–27.31) (27 | Q3 (27.32–28.90) | Q4 diff (≥28.91) | p ror difference ¹ | p ror trend ² |
| Acg (W) 53.0450.3 54.445.0 50.0450.3 54.445.0 50.045 56.44.84 60.01 50.010 50.344.84 Meight ((m) 57.34.10 71.34.10 56.34.84 60.001 60.001 62.448.6 Meight ((m) 57.34.10 71.34.11 20.34.15.6 57.14.21 20.34.45.6 60.011 60.001 60.001 62.44.86 Mist circumference (cm) 22.14.3.0 22.74.3.6 57.14.21 20.34.45.1 60.011 60.001 | | | | | | | 100.0 |
| Height (m) Triand Could is | | 4.CT0.CC | | 03.9±0.1 | | <0.001 | <0.001 |
| Weight (kg) 553 ± 10 713 ± 10 713 ± 10 713 ± 10 551 ± 21 325 ± 34 60011 $c0001$ $c001$ | | 154.1±4.6 | | 58.0±4.5 | | <0.001 | <0.001 |
| $ \begin{array}{llllllllllllllllllllllllllllllllllll$ | | 62.4±8.6 | | 57.3±6.3 | | <0.001 | <0.001 |
| Mast circumference (cm) 22.1 ± 73 8.70 ± 50 8.44 ± 55 6001 $c0001$ 60011 553 ± 20 Systolic BP (mmHg) 22.8 ± 10.1 22.8 ± 36 12.8 ± 14.8 12.85 ± 14.8 12.85 ± 14.8 12.85 ± 14.8 12.85 ± 14.8 12.85 ± 16.1 38.75 ± 16.8 6001 $c0001$ 553 ± 53 Diastolic BP (mmHg) 8.25 ± 10.1 38.82 ± 13 10.91 ± 16.1 10.11 0011 2001 20001 553 ± 53 T (mg/dl) 12.85 ± 10.3 48.8 ± 11.3 50.2041 12.10 ± 33.3 111.8 ± 27.4 0001 $c0001$ $50.92.948$ TG (mg/dl) $150(10.7-2041)$ $135(96-2041)$ $135(95-204)$ 12.10 ± 33.3 111.8 ± 27.4 0001 $c0001$ 59.428 TG (mg/dl) $150(10.7-204)$ $135(96-204)$ $124(93-1.60)$ 114.8 ± 17.7 59.428 TG (mg/dl) $150(10.7-204)$ $135(96-204)$ $124(93-1.60)$ 0001 0001 0001 59.428 TG (mg/dl) $112(97.2)$ $1117(1.2)$ $07(10-1.2)$ $07(11.2)$ <td></td> <td>26.2±2.9</td> <td>24.0±2.2</td> <td>22.9±1.9</td> <td>21.5±1.7 <(</td> <td><0.001</td> <td><0.001</td> | | 26.2±2.9 | 24.0±2.2 | 22.9±1.9 | 21.5±1.7 <(| <0.001 | <0.001 |
| ASM (kg) 221 ± 3.0 227 ± 2.6 231 ± 3.4 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 > 0.001 <t< td=""><td></td><td>84.4±8.0</td><td>79.3±6.6</td><td>77.0±6.0</td><td>73.1±5.5 <(</td><td><0.001</td><td><0.001</td></t<> | | 84.4±8.0 | 79.3±6.6 | 77.0±6.0 | 73.1±5.5 <(| <0.001 | <0.001 |
| Systolic BP (mmHq) 128.7±14.8 12.5.0±14.6 12.9.2±13.1 12.0.9±13.5 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 | | 15.3±2.0 | 15.6±1.9 | 16.1±1.8 | 16.8±2.2 <(| <0.001 | <0.001 |
| $ \begin{array}{llllllllllllllllllllllllllllllllllll$ | | ľ | 117.8±13.8 1 | 114.6±13.6 | 111.1±14.3 <(| <0.001 | <0.001 |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | | 75.3±8.5 | 74.2±8.8 | 73.0±8.8 | 71.2±8.7 <(| <0.001 | <0.001 |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | 201.3±35.0 20 | 205.1 ± 35.3 | 195.9±31.9 (| 0.001 | 0.002 |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | 56.8±13.3 | 58.3±13.7 (| 60.3±13.7 | 63.8±14.9 <(| <0.001 | <0.001 |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | | | 121.4±31.7 12 | 123.2±29.9 | 113.0±28.0 <(| <0.001 | <0.001 |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | | | 108 [82-141] 100 | 100 [75-138] | 86 [66-117] <(| <0.001 | <0.001 |
| Fasting glucose (mg/dL) 97 [87-106] 90 [84-97] 90 [85-98] 92 [85-100] <0.001 <0.001 50.64.05 55.64.05 55.74.06 0.001 <0.001 50.64.05 55.64.05 55.74.06 0.001 <0.001 50.64.05 55.40.05 55.41.03 55.41.23 56.41.23 57.41.23 56.41.23 57.41.23 56.41.23 57.42.23 57.41.23 56.41.23 57.42.23 57.42.23 57.42.23 57.42.23 57.42.23 57.42.23 57.42.23 57.42.23 57.42.23 57.42.23 57.42.23 57.42.23 57.42.23 57.42.23 57.42.23 57.42.23< | | 3.8±0.9 | 3.6±0.8 | 3.5±0.8 | 3.2±0.8 <(| <0.001 | <0.001 |
| Hemoglobin Alc (%) 6.0 ± 1.1 5.7 ± 0.8 5.6 ± 0.5 5.7 ± 0.6 0.001 -0.001 5.9 ± 0.8 Creactive protein (mg/L)1.1 $[0.6+1.7]$ 0.7 0.7 0.6 $1.0.6$ 0.2 0.001 -0.001 5.9 ± 0.8 IMT (mm) 0.7 0.7 1.1 $[0.6+1.7]$ 0.7 0.81 ± 0.099 0.57 ± 0.11 0.65 0.001 -0.001 0.678 ± 0.095 Highest quartile of IMT 5.4 3.6 3.6 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 Highest quartile of IMT 5.4 3.6 3.6 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 Highest quartile of IMT 5.4 3.5 3.6 2.2 3.6 2.0 0.01 -0.001 5.03 3.2 Antihypertensive medication 1.7 1.1 7.4 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 Antihypertensive medication 1.7 1.7 3.7 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 Antihypertensive medication 1.7 1.7 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 Antihypertensive medication 1.7 1.7 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 <th< td=""><td></td><td></td><td>88 [83-94] 8</td><td>87 [82-93]</td><td>86 [81-91] <(</td><td><0.001</td><td><0.001</td></th<> | | | 88 [83-94] 8 | 87 [82-93] | 86 [81-91] <(| <0.001 | <0.001 |
| Creactive protein (mg/L) 1.1 [0.6-1.7] 0.7 [0.4-1.2] 0.6 [0.3-1.1] 0.5 [0.3-1.0] 0.28 0.20 0.9 [0.5-2.0] IMT (mm) 0.711±0.115 0.881±0.099 0.672±0.110 0.662±0.097 0.001 6678±0.093 0.678±0.093 0.678±0.093 0.678±0.093 0.678±0.093 0.678±0.093 0.678±0.091 96(30.2) 28(18.9) 23(15.4) <0.001 | | 5.9±0.8 | 5.8±0.6 | 5.7±0.6 | · | <0.001 | <0.001 |
| IMT (mm) 0.711±0.115 0.681±0.099 0.672±0.110 0.662±0.097 0.001 6.001 0.678±0.095 Highest quartile of IMT 54 (36.5) 36 (24.2) 37 (24.8) 23 (15.4) 0.001 0.012 0.678±0.095 Antihypertensive medication 47 (31.8) 39 (26.5) 36 (24.1) 37 (24.8) 23 (15.4) 0.001 0.65 (30.2) Antihypertensive medication 47 (31.8) 39 (26.1) 11 (7.4) 8 (5.4) 9 (6.0) 0.11 0.02 0.501 73 (33.0) Antihypertensive medication 17 (11.5) 11 (7.4) 8 (5.4) 9 (6.0) 0.11 0.02 23 (7.2) Antihypertensive medication 37 (31.0) 15 (10.1) 15 (10.1) 15 (10.1) 9 (6.0) 0.11 0.02 37 (25.0) Non-smoker 37 (35.0) 65 (33.6) 65 (43.3) 0.32 (37.2) 30 (95.0) 30 (95.0) Current smoker 76 (51.3) 77 (51.7) 65 (33.6) 64 (43.3) 0.10 0.02 37 (95.0) Current smoker 76 (7.1) 1 | | | 0.6 [0.4-1.2] 0. | 0.5 [0.3-0.9] | 0.4 [0.3-0.8] | 0.004 | <0.001 |
| Highest quartile of IMT $54 (36.5)$ $36 (24.2)$ $37 (24.8)$ $23 (15.4)$ 0.001 0.001 $96 (30.2)$ Carotid plaque $44 (29.5)$ $36 (24.2)$ $30 (20.1)$ $28 (18.9)$ 0.12 0.02 $45 (14.2)$ Antihypertensive medication $17 (11.5)$ $11 (7.4)$ $8 (5.4)$ $9 (6.0)$ 0.22 0.06 $23 (7.2)$ Antidiabetic medication $17 (11.5)$ $11 (7.4)$ $8 (5.4)$ $9 (6.0)$ 0.22 0.06 $23 (7.2)$ Antidiabetic medication $22 (14.9)$ $15 (10.1)$ $15 (10.1)$ $9 (6.0)$ 0.11 0.02 0.06 $23 (7.2)$ Smoking status $22 (14.9)$ $15 (10.1)$ $15 (10.1)$ $9 (6.0)$ 0.11 0.02 0.06 $23 (7.2)$ Non-smoker $32 (23.7)$ $29 (195)$ $41 (27.5)$ $32 (21.5)$ 0.34 0.10 $30 (95.0)$ Former smoker $37 (25.0)$ $43 (28.9)$ $41 (27.5)$ $32 (21.5)$ 0.34 0.10 $30 (95.0)$ Non-drinker $37 (25.0)$ $43 (28.9)$ $41 (27.5)$ $32 (21.5)$ 0.34 0.10 $30 (95.0)$ Non-drinker $7 (4.7)$ $18 (7.1)$ $10 (71.1)$ 0.02 0.72 $13 (4.1)$ Non-drinker $12 (32.3)$ $11 (77.8)$ $127 (85.2)$ 0.72 $13 (4.1)$ Non-drinker $12 (3.2)$ $12 (70.5)$ $9 (6.0)$ $127 (85.2)$ $3 (7.9)$ Non-drinker $12 (32.3)$ $11 (77.8)$ $12 (72.8)$ $12 (72.8)$ $10 (71.1)$ Non-drinker </td <td></td> <td>0.678±0.095 0</td> <td>0.669±0.105 0.</td> <td>0.657±0.098</td> <td>0.632±0.100 <(</td> <td><0.001</td> <td><0.001</td> | | 0.678±0.095 0 | 0.669±0.105 0. | 0.657±0.098 | 0.632±0.100 <(| <0.001 | <0.001 |
| Carotid plaque 44 (29.5) 36 (24.2) 30 (20.1) 28 (18.8) 0.12 0.02 45 (14.2) Antihypertensive medication 17 (11.5) 11 (7.4) 8 (5.4) 9 (6.0) 0.02 0.06 23 (7.2) Ipid-lowering medication 17 (11.5) 11 (7.4) 8 (5.4) 9 (6.0) 0.01 <0.00 | | 96 (30.2) | 90 (28.2) | 77 (24.1) | 58 (18.2) (| 0.003 | <0.001 |
| Antihypertensive medication 47 (31.8) 39 (26.2) 28 (18.8) 20 (13.4) <0.001 73 (23.0) Antidiabetic medication 17 (11.5) 11 (7.4) 8 (5.4) 9 (6.0) 0.22 0.06 23 (7.2) Lipid-lowering medication 27 (11.5) 11 (7.4) 8 (5.4) 9 (6.0) 0.11 0.02 0.06 23 (7.2) Smoking status 25 (13.3) 77 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 30 (9.0) 30 (9.0) Non-smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 31 (4.1) 31 (4.1) Current smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 32 (21.6) 33 (9.0) Durent smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 32 (21.6) 33 (9.1) Current smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 32 (21.6) 33 (9.1) Current smoker 76 (51.7) 13 (21.8) 13 (21.6) 9 (6.1) 13 (21.6) 13 (41.1) Current smoker | | 45 (14.2) | 40 (12.6) | 29 (9.1) | 23 (7.2) (| 0.019 | <0.001 |
| Antidiabetic medication 17 (11.5) 11 (7.4) 8 (5.4) 9 (6.0) 0.22 0.06 23 (7.2) Lipid-lowering medication 22 (14.9) 15 (10.1) 15 (10.1) 9 (6.0) 0.11 0.02 57 (17.9) Smoking status 35 (23.7) 29 (19.5) 41 (27.5) 32 (21.5) 0.34 0.10 302 (95.0) Former smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 3 (0.9) Current smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 3 (0.9) Current smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 3 (0.9) Current smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 3 (0.9) Current smoker 7 (4.7) 13 (8.7) 13 (8.7) 0.55 0.72 13 (41.9) Non-drinker 7 (4.7) 13 (8.7) 14 (9.4) 9 (6.1) 10 (6.1) 10 (71.1) Regular exercise 85 (57.4) 119 (79.9) 116 (77.8) 127 (85.2) 10 (6.1) 10 (6.1) <td></td> <td>73 (23.0)</td> <td>66 (20.7)</td> <td>39 (12.2)</td> <td>29 (9.1) <(</td> <td><0.001</td> <td><0.001</td> | | 73 (23.0) | 66 (20.7) | 39 (12.2) | 29 (9.1) <(| <0.001 | <0.001 |
| Lipid-lowering medication 22 (14.9) 15 (10.1) 15 (10.1) 9 (6.0) 0.11 0.02 57 (17.9) Smoking status 35 (23.7) 29 (19.5) 41 (27.5) 32 (21.5) 0.34 0.10 302 (95.0) Non-smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 13 (4.1) Former smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 302 (95.0) Torner smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 302 (95.0) Torner smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 302 (95.0) Torner smoker 37 (25.0) 43 (28.8) 43 (28.9) 51 (34.2) 31 (41.9) Drinking status 18 (12.2) 17 (11.4) 19 (12.8) 13 (8.7) 0.55 0.72 133 (41.9) Former drinker 7 (4.7) 13 (8.7) 14 (9.4) 9 (6.1) 10 (3.1) 10 (3.1) Regular exercise 85 (57.4) 119 (79.9) 116 (77.8) 127 (85.2) 10 (3.1) No< | | 23 (7.2) | 10 (3.1) | 9 (2.8) | | 0.006 | 0.003 |
| Smoking status 35 (23.7) 29 (19.5) 41 (27.5) 32 (21.5) 0.34 0.10 302 (95.0) Non-smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 13 (4.1) Former smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 13 (4.1) Current smoker 7 (51.2) 43 (28.8) 43 (28.9) 51 (34.2) 30 (95.0) Drinking status 37 (25.0) 43 (28.8) 43 (28.9) 51 (34.2) 31 (4.1) Non-drinker 7 (4.7) 17 (11.4) 19 (12.8) 13 (8.7) 0.55 0.72 133 (41.9) Non-drinker 7 (4.7) 13 (8.7) 14 (9.4) 9 (6.1) 10 (3.1) 10 (3.1) Regular exercise 85 (57.4) 119 (79.9) 116 (77.8) 127 (85.2) 133 (41.5) 10 (3.1) No 63 (42.6) 60 (6.4) 10.6 (71.1) 0.02 0.09 135 (41.5) 10 (3.1) No 63 (42.6) 44 (29.5) 59 (39.4) 43 (28.9) 133 (41.5) 105 (71.5) 106 (71. | | 57 (17.9) | 66 (20.7) | 38 (12.0) | 22 (6.9) <(| <0.001 | <0.001 |
| Non-smoker 35 (23.7) 29 (19.5) 41 (27.5) 32 (21.5) 0.34 0.10 302 (95.0) Former smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 13 (4.1) Current smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 302 (95.0) Current smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 302 (95.0) Drinking status 37 (25.0) 43 (28.8) 43 (28.9) 51 (34.2) 30 (9) Non-drinker 7 (4.7) 13 (8.7) 19 (12.8) 13 (8.7) 0.55 0.72 133 (41.9) Former drinker 7 (4.7) 13 (8.7) 14 (9.4) 9 (6.1) 10 (3.1) 10 (3.1) Regular exercise 85 (57.4) 119 (79.9) 116 (77.8) 127 (85.2) 10.6) 132 (41.5) No 63 (42.6) 60 (60.4) 106 (71.1) 0.02 0.09 132 (41.5) No 63 (42.6) 44 (29.5) 59 (39.4) 43 (28.9) 132 (41.5) No 63 (42.6) | | | | | | | |
| Former smoker 76 (51.3) 77 (51.7) 65 (43.6) 66 (44.3) 13 (4.1) Current smoker 37 (25.0) 43 (28.8) 43 (28.9) 51 (34.2) 3 (0.9) Drinking status Non-drinker 37 (25.0) 43 (28.8) 43 (28.9) 51 (34.2) 3 (0.9) Drinking status Non-drinker 18 (12.2) 17 (11.4) 19 (12.8) 13 (8.7) 0.55 0.72 133 (41.9) Former drinker 7 (4.7) 13 (8.7) 14 (9.4) 9 (6.1) 10 (3.1) 10 (3.1) Regular exercise 85 (57.4) 119 (79.9) 116 (77.8) 127 (85.2) 175 (55.0) Regular exercise 85 (57.4) 105 (70.5) 90 (60.4) 106 (71.1) 0.02 0.09 132 (41.5) No 63(42.6) 6.9±1.3 7.1±1.1 6.8±1.1 0.09 132 (41.5) 132 (41.5) Renopause 85 (57.4) 105 (70.5) 90 (60.4) 106 (71.1) 0.02 0.09 132 (41.5) No 63(42.6) 7.1±1.1 6.8±1.1 0.00 <td></td> <td>302 (95.0)</td> <td>304 (95.3)</td> <td>304 (95.3)</td> <td>297 (93.4) (</td> <td>0.28</td> <td>0.02</td> | | 302 (95.0) | 304 (95.3) | 304 (95.3) | 297 (93.4) (| 0.28 | 0.02 |
| Current smoker 37 (25.0) 43 (28.8) 43 (28.9) 51 (34.2) 3 (0.9) Drinking status Non-drinker 17 (11.4) 19 (12.8) 13 (8.7) 0.55 0.72 133 (41.9) Non-drinker 7 (4.7) 13 (8.7) 14 (9.4) 9 (6.1) 10 (3.1) Former drinker 7 (4.7) 13 (8.7) 14 (9.4) 9 (6.1) 105 (7.9) 10 (3.1) Regular exercise 7 (4.7) 13 (8.7) 116 (77.8) 127 (85.2) 105 (7.1) 105 (7.0) Regular exercise 85 (57.4) 105 (70.5) 90 (60.4) 106 (71.1) 0.02 0.09 186 (58.5) No $63(42.6)$ $44(29.5)$ $59(39.4)$ $432(28.9)$ 132 (41.5) Sleep duration (hr/d) 7.1 ± 1.3 6.9 ± 1.3 7.1 ± 1.1 6.8 ± 1.1 0.09 132 (41.5) Menopause 85 (37.4) 7.1 ± 1.3 6.9 ± 1.3 7.1 ± 1.1 6.8 ± 1.1 264 (83.0) Menopause 7.1 ± 1.3 6.9 ± 1.3 <t< td=""><td></td><td>13 (4.1)</td><td>8 (2.5)</td><td>8 (2.5)</td><td>9 (2.8)</td><td></td><td></td></t<> | | 13 (4.1) | 8 (2.5) | 8 (2.5) | 9 (2.8) | | |
| Drinking status 18 (12.2) 17 (11.4) 19 (12.8) 13 (8.7) 0.55 0.72 133 (41.9) Non-drinker 7 (4.7) 13 (8.7) 14 (9.4) 9 (6.1) 10 (3.1) Former drinker 7 (4.7) 13 (8.7) 14 (9.4) 9 (6.1) 10 (3.1) Regular drinker 123 (83.1) 119 (79.9) 116 (77.8) 127 (85.2) 105 (55.0) Regular exercise 85 (57.4) 105 (70.5) 90 (60.4) 106 (71.1) 0.02 0.09 186 (58.5) No 63(42.6) 44(29.5) 59(39.4) 43(28.9) 132 (41.5) 132 (41.5) Sleep duration (hr/d) 7.1±1.3 6.9±1.3 7.1±1.1 6.8±1.1 0.09 132 (41.5) Menopause 7.1±1.3 6.9±1.3 7.1±1.1 6.8±1.1 0.09 0.11 6.8±1.3 | | 3 (0.9) | 7 (2.2) | 7 (2.2) | 12 (3.8) | | |
| Non-drinker 18 (12.2) 17 (11.4) 19 (12.8) 13 (8.7) 0.55 0.72 133 (41.9) Former drinker 7 (4.7) 13 (8.7) 14 (9.4) 9 (6.1) 0.55 0.72 133 (41.9) Current regular drinker 123 (8.7) 13 (8.7) 14 (9.4) 9 (6.1) 10 (3.1) Regular exercise 7 (4.7) 13 (8.7) 116 (77.8) 127 (85.2) 105 (55.0) Regular exercise 85 (57.4) 105 (70.5) 90 (60.4) 106 (71.1) 0.02 0.09 186 (58.5) No 63(42.6) 44(29.5) 59(39.4) 43(28.9) 132 (41.5) 32(41.5) Sleep duration (hr/d) 7.1±1.3 6.9±1.3 7.1±1.1 6.8±1.1 0.09 0.11 6.8±1.5 Menopause X.1±1.1 6.8±1.1 0.09 0.11 264 (83.0) | | | | | | | |
| Former drinker 7 (4,7) 13 (8.7) 14 (9.4) 9 (6.1) 10 (3.1) Current regular drinker 123 (83.1) 119 (79.9) 116 (77.8) 127 (85.2) 175 (55.0) Regular exercise 85 (57.4) 105 (70.5) 90 (60.4) 106 (71.1) 0.02 0.09 186 (58.5) No 63(42.6) 44(29.5) 59(39.4) 43(28.9) 132 (41.5) 132 (41.5) Sleep duration (hr/d) 7.1±1.3 6.9±1.3 7.1±1.1 6.8±1.1 0.09 132 (41.5) Menopause X.1±1.1 6.8±1.1 0.09 0.11 6.8±1.3 Values are presented as mean±standard deviation, median [interquartile range], or number (%). 264 (83.0) X4MW* anomoticiular skelerial muscle mass/weight: BMI bodv mass index BP, blood pressure: T. total cholesterol: HDLC. high-densitive the mass/weight: BMI bodv mass index BP, blood pressure: T. total cholesterol: HDLC. high-densitive the mass/weight: BMI bodv mass index BP, blood pressure: T. total cholesterol: HDLC. high-densitive the mass/weight: BMI bodv mass index BP, blood pressure: T. total cholesterol: HDLC. high-densitive the mass/weight: BMI bodv mass index BP, blood pressure: T. total cholesterol: HDLC. high-densitive the mass/weight: BMI bodv mass index BP, blood pressure: T. total cholesterol: HDLC. high-densitive theologe theolesterol: HDLC. High-densitive theologe the mass/wei | | 133 (41.9) | | 134 (42.0) | | 0.76 | 0.30 |
| Current regular drinker 123 (83.1) 119 (79.9) 116 (77.8) 127 (85.2) 175 (55.0) Regular exercise 85 (57.4) 105 (70.5) 90 (60.4) 106 (71.1) 0.02 0.09 186 (58.5) Vo 63(42.6) 44(29.5) 59(39.4) 43(28.9) 132 (41.5) Sleep duration (hr/d) 7.1±1.3 6.9±1.3 7.1±1.1 6.8±1.1 0.09 132 (41.5) Menopause X.1±1.3 6.9±1.3 7.1±1.1 6.8±1.1 0.09 0.11 6.8±1.3 Values are presented as mean±standard deviation, median [interquartile range], or number (%). X64 (83.0) X64 (83.0) | | 10 (3.1) | | 9 (2.8) | 10 (3.1) | | |
| Regular exercise 85 (57.4) 105 (70.5) 90 (60.4) 106 (71.1) 0.02 0.09 186 (58.5) No 63(42.6) 44(29.5) 59(39.4) 43(28.9) 132 (41.5) Sleep duration (hr/d) 7.1±1.3 6.9±1.3 7.1±1.1 6.8±1.1 0.09 132 (41.5) Menopause 7.1±1.3 6.9±1.3 7.1±1.1 6.8±1.1 264 (83.0) Values are presented as mean±standard deviation, median [interquartile range], or number (%). 264 (83.0) 264 (83.0) | | 175 (55.0) | 185 (58.0) | 176 (55.2) | 192 (60.4) | | |
| Yes 85 (57.4) 105 (70.5) 90 (60.4) 106 (71.1) 0.02 0.09 186 (58.5) No 63(42.6) 44(29.5) 59(39.4) 43(28.9) 132 (41.5) Sleep duration (hr/d) 7.1±1.3 6.9±1.3 7.1±1.1 6.8±1.1 0.09 132 (41.5) Menopause 7.1±1.3 6.9±1.3 7.1±1.1 6.8±1.1 0.09 0.11 6.8±1.3 Values are presented as mean±standard deviation, median [interquartile range], or number (%). 264 (83.0) 264 (83.0) | | | | | | | |
| No 63(42.6) 44(29.5) 59(39.4) 43(28.9) 132 (41.5) Sleep duration (hr/d) 7.1±1.3 6.9±1.3 7.1±1.1 6.8±1.1 0.09 0.11 6.8±1.3 Menopause 264 (83.0) 264 (83.0) 264 (83.0) 264 (83.0) Values are presented as mean±standard deviation, median [interquartile range], or number (%). 264 (83.0) 264 (83.0) | | 186 (58.5) | _ | 202 (63.3) | | 0.32 | 0.07 |
| Sleep duration (hr/d) 7.1±1.3 6.9±1.3 7.1±1.1 6.8±1.1 0.09 0.11 6.8±1.3 Menopause 264 (83.0) Values are presented as mean±standard deviation, median [interquartile range], or number (%). 264 (83.0) AstMVMt annendicular skeletral muscle mass/weight: BML bodv mass index BP, blood pressure: TC. total cholesterol: HDLC. high-densiti | | 132 (41.5) | 121 (37.9) | 117 (36.7) | 110 (34.6) | | |
| Menopause Values are presented as mean±standard deviation, median [interquartile range], or number (%). ASMVMr annendirular skeleral muscle mass/weight: BML bodv mass index: BP, blood pressure: TC. total cholesterol: HDLC. high-densit | | 6.8±1.3 | 6.9±1.1 | 6.8±1.2 | | 0.40 | 0.46 |
| Values are presented as mean±standard deviation, median [interquartile range], or number (%). ASMVMt amendicular skeleral muscle mass/weight: BML bodv mass index: BP, blood pressure: TC. total cholesterol: HDLC. high-densit | | 264 (83.0) | 247 (77.4) | 227 (71.2) | 187 (58.8) <(| <0.001 | <0.001 |
| ASM/WF annendicular skeletal muscle mass/weight: BMI. body mass index: BP blood pressure: TC. total cholesterol: HDLC. high-density | | | | | | | |
| and working the board of | tal cholesterol; HDL0 | C, high-density lipe | oprotein cholest | erol; LDLC, lov | /-density lipoprote | ein cholest | erol; TG, |
| triglycerides; IMT, intima-media thickness. 11 leinor 1. uros sensivies of variance, the Kurchall Mallie toot, ar the chi course toot | | | | | | | |
| . 'Using 1-way analysis of variance, the Kutskan-Wulls test, for the Chn-square test. "Trans - cranted intervent and the contract and the contract of the formation of | | | | | | | |

Heo JE et al. : ASM mass and carotid arterial wall thickness

www.e-epih.org | 3

exceeding 1.0 mm or \geq 50% thicker than that of the surrounding vessel wall.

Statistical analysis

All analyses were performed separately for men and women because both ASM/Wt and IMT differed significantly by gender (Supplementary Material 1). We evaluated differences in demographic characteristics among the 4 groups based on the ASM/Wt quartiles and used 1-way analysis of variance for normally distributed variables, the Kruskal-Wallis test for skewed variables, and the chi-square test for categorical variables. The p for trend was calculated using a contrast to test for linear trends in continuous variables and the Cochran-Armitage test for categorical variables. The association between ASM/Wt and the highest quartile of IMT was assessed in people with lower (<25.0 kg/m²) and higher BMIs (\geq 25.0 kg/m²) because there was a significant interaction between ASM/Wt quartiles and BMI categories in the presence of the highest quartile of IMT (Supplementary Material 2). Multivariable logistic regression analyses were used to assess the independent effect of ASM/Wt (using gender-specific quartiles) on the

Table 2. Association between ASM/Wt and the highest quartile of IMT according to BMI categories

| | No. of people | People with the highest quartile of IMT | Age-adjusted | Fully adjusted ¹ |
|---------------------------|---------------|--|--------------------|-----------------------------|
| Ven (n=595) | | | | |
| BMI <25 kg/m ² | | | | |
| ASM/Wt (quartiles) | | | | |
| Q4 | 126 | 15 (11.9) | 1.00 (reference) | 1.00 (reference) |
| Q3 | 102 | 20 (19.6) | 1.78 (0.84, 3.79) | 1.59 (0.72, 3.50) |
| Q2 | 75 | 17 (22.7) | 2.04 (0.92, 4.52) | 1.81 (0.78, 4.17) |
| Q1 | 36 | 14 (38.9) | 3.21 (1.32, 7.82) | 2.78 (1.09, 7.13) |
| ASM/Wt (continuous) | | | | |
| Per 10% decrease | 339 | 66 (19.5) | 4.32 (1.12, 16.71) | 3.26 (0.78, 13.68) |
| BMI ≥25 kg/m ² | | | | |
| ASM/Wt (quartiles) | | | | |
| Q4 | 23 | 8 (34.8) | 1.00 (reference) | 1.00 (reference) |
| Q3 | 47 | 17 (36.2) | 0.99 (0.35, 2.76) | 0.91 (0.25, 2.96) |
| Q2 | 74 | 19 (25.7) | 0.56 (0.19, 1.65) | 0.42 (0.14, 1.34) |
| Q1 | 112 | 40 (35.7) | 0.99 (0.35, 2.76) | 0.59 (0.24, 1.91) |
| ASM/Wt (continuous) | | | | |
| Per 10% decrease | 256 | 84 (32.8) | 1.27 (0.48, 3.35) | 0.82 (0.30, 2.22) |
| Vomen (n=1,274) | | | | |
| BMI <25 kg/m ² | | | | |
| ASM/Wt (quartiles) | | | | |
| Q4 | 307 | 56 (18.3) | 1.00 (reference) | 1.00 (reference) |
| Q3 | 271 | 58 (21.4) | 1.01 (0.66, 1.55) | 0.90 (0.57, 1.42) |
| Q2 | 225 | 56 (24.9) | 1.10 (0.71, 1.70) | 0.96 (0.62, 1.52) |
| Q1 | 122 | 30 (24.6) | 0.95 (0.56, 1.61) | 0.85 (0.49, 1.47) |
| ASM/Wt (continuous) | | | | |
| Per 10% decrease | 925 | 200 (21.6) | 1.19 (0.62, 2.26) | 1.14 (0.61, 2.12) |
| BMI ≥25 kg/m² | | | | |
| ASM/Wt (quartiles) | | | | |
| Q4 | 11 | 2 (18.2) | 1.00 (reference) | 1.00 (reference) |
| Q3 | 48 | 19 (39.6) | 2.44 (0.47, 12.87) | 2.62 (0.44, 14.99) |
| Q2 | 94 | 34 (36.2) | 1.89 (0.37, 9.46) | 1.71 (0.31, 9.79) |
| Q1 | 196 | 66 (33.7) | 1.63 (0.34, 8.01) | 1.44 (0.27, 8.11) |
| ASM/Wt (continuous) | | , | , , , , | |
| Per 10% decrease | 349 | 121 (34.7) | 0.66 (0.22, 2.05) | 0.61 (0.19, 1.80) |

Values are presented as number (%) or odds ratio (95% confidence interval).

ASM/Wt, appendicular skeletal muscle mass/weight; BMI, body mass index.

¹Adjusted for age, menopause, systolic blood pressure, hemoglobin A1c, total/high-density lipoprotein cholesterol ratio, C-reactive protein, smoking, drinking, and regular exercise.

likelihood of being in highest quartile of IMT according to BMI categories in both age-adjusted and fully adjusted models (age, menopause, systolic blood pressure, HbA1c, TC/HDLC, C-reactive protein, smoking, drinking, and regular exercise). ASM/Wt was also analyzed as a continuous variable in association with the highest quartile of IMT. Additionally, the same multivariable logistic regression analyses were conducted to determine the association between ASM/Wt (using gender-specific quartiles and continuous variables) and carotid artery plaque according to BMI categories. Lastly, we estimated the odds ratio (OR) and 95% confidence interval (CI) for being in the highest quartile of IMT according to the 8 combined categories of ASM/Wt (quartiles) and BMI (<25.0 or \geq 25.0 kg/m²) after fully adjusting for confounders. The reference group comprised participants with lower BMIs in the highest ASM/Wt quartile. All statistical tests were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA), and statistical significance was defined as a 2-sided p-value of <0.05.

Table 3. Association between ASM/Wt and carotid plaque according to BMI categories

| | No. of people | People with carotid plaque | Age-adjusted | Fully adjusted ¹ |
|---------------------------|---------------|-------------------------------|--------------------|-----------------------------|
| Men (n=595) | | | | |
| BMI <25 kg/m ² | | | | |
| ASM/Wt (quartiles) | | | | |
| Q4 | 125 | 21 (16.8) | 1.00 (reference) | 1.00 (reference) |
| Q3 | 103 | 18 (17.5) | 1.03 (0.52, 2.07) | 1.05 (0.51, 2.15) |
| Q2 | 74 | 16 (21.6) | 1.32 (0.64, 2.74) | 1.17 (0.54, 2.53) |
| Q1 | 37 | 15 (40.5) | 2.96 (1.30, 6.77) | 2.48 (1.04, 5.90) |
| ASM/Wt (continuous) | | | | |
| Per 10% decrease | 339 | 70 (20.7) | 4.19 (1.13, 15.56) | 3.27 (0.85, 12.57) |
| BMI ≥25 kg/m² | | | | |
| ASM/Wt (quartiles) | | | | |
| Q4 | 23 | 7 (30.4) | 1.00 (reference) | 1.00 (reference) |
| Q3 | 46 | 12 (26.1) | 0.74 (0.23, 2.33) | 0.52 (0.16, 1.74) |
| Q2 | 75 | 20 (26.7) | 0.74 (0.25, 2.14) | 0.53 (0.17, 1.63) |
| Q1 | 112 | 29 (25.9) | 0.76 (0.27, 2.10) | 0.41 (0.13, 1.24) |
| ASM/Wt (continuous) | | | | |
| Per 10% decrease | 256 | 68 (26.6) | 1.39 (0.50, 3.91) | 0.90 (0.32, 2.55) |
| Vomen (n=1,274) | | | | |
| BMI <25 kg/m ² | | | | |
| ASM/Wt (quartiles) | | | | |
| Q4 | 308 | 23 (7.5) | 1.00 (reference) | 1.00 (reference) |
| Q3 | 270 | 25 (9.3) | 1.12 (0.62, 2.05) | 0.90 (0.49, 1.69) |
| Q2 | 225 | 22 (9.8) | 1.11 (0.81, 2.07) | 0.88 (0.46, 1.67) |
| Q1 | 122 | 11 (9.0) | 0.93 (0.67, 20.1) | 0.70 (0.32, 1.56) |
| ASM/Wt (continuous) | | | | |
| Per 10% decrease | 925 | 81 (8.8) | 0.77 (0.36, 1.67) | 0.62 (0.29, 1.31) |
| BMI ≥25 kg/m ² | | | | |
| ASM/Wt (quartiles) | | | | |
| Q4 | 11 | 0 (0.0) | 1.00 (reference) | 1.00 (reference) |
| Q3 | 48 | 4 (8.3) | NA | NA |
| Q2 | 94 | 18 (19.2) | NA | NA |
| Q1 | 196 | 34 (17.4) | NA | NA |
| ASM/Wt (continuous) | | | | |
| Per 10% decrease | 349 | 56 (16.1) | 2.25 (0.48, 10.47) | 2.40 (0.47, 12.18) |

Values are presented as number (%) or odds ratio (95% confidence interval).

ASM/Wt, appendicular skeletal muscle mass/weight; BMI, body mass index; OR, odds ratio; CI, confidence interval; NA, not applicable. ¹Adjusted for age, menopause, systolic blood pressure, hemoglobin A1c, total/high-density lipoprotein cholesterol ratio, C-reactive protein, smoking, drinking, and regular exercise.

RESULTS

Table 1 presents the characteristics of the men and women study participants according to ASM/Wt quartiles. Both men and women in the lower ASM/Wt quartiles tended to have a higher BMI, waist circumference, blood pressure, lipid levels, glucose level, IMT, frequencies of the highest quartile of IMT, and carotid artery plaque. However, higher ASM/Wt quartiles were not significantly associated with smoking, drinking status, or sleep duration in either gender.

Table 2 presents the results of multivariable logistic regression analyses stratified by BMI categories. In the age-adjusted logistic regression model, the risk of being in the highest quartile of IMT among men with lower BMIs was significantly higher in the lowest ASM/Wt quartile (OR, 3.21; 95% CI, 1.32 to 7.82) relative to the highest ASM/Wt quartile. After adjusting for age, systolic blood pressure, HbA1c, TC/HDLC, C-reactive protein, smoking, drinking, and regular exercise, this association was weakened but remained statistically significant (OR, 2.78; 95% CI, 1.09 to 7.13). When continuous variables were examined in the age-adjusted model, each 10% decrease in ASM/Wt (OR, 4.32; 95% CI, 1.12 to 16.71) was inversely associated with being in the highest quartile of IMT in men with lower BMIs. After adjusting for additional CVD risk factors, the association became non-significant. Among men with higher BMIs, the risk of being in the highest quartile of IMT was lower in other ASM/Wt quartiles than in the highest ASM/Wt quartile, although this association was not significant. Among women, there was no significant association between ASM/Wt and being in the highest quartile of IMT, regardless of BMI category.

The results for using carotid artery plaque as an outcome variable were similar to those of using the highest quartile of IMT. After adjusting for CVD risk factors, the risk of carotid artery plaque among men with lower BMIs was significantly higher in the lowest ASM/Wt quartile (OR, 2.48; 95% CI, 1.04 to 5.90) than in the highest ASM/Wt quartile. Among men with higher BMIs, the risk of carotid artery plaque was lower in other ASM/Wt quartiles than in the highest ASM/Wt quartile, although this association was not significant. Among women, there was no significant association between ASM/Wt and carotid artery plaque, regardless of




Figure 1. ORs for higher quartile of IMT according to the eight combined categories of ASM/Wt and BMI by gender (A: men, B: women). ORs (95% CIs) adjusted for age, menopause, systolic blood pressure, hemoglobin A1c, total/high-density lipoprotein cholesterol ratio, smoking, drinking, and regular exercise are shown. The reference group comprised individuals with a BMI of <25 kg/m² and an ASM/Wt in the highest quartile. BMI, body mass index; ASM/Wt, appendicular skeletal muscle mass/weight; OR, odds ratio; CI, confidence interval; IMT, intima-media thickness.

BMI category (Table 3).

We estimated the OR for being in the highest quartile of IMT according to the 8 combined categories of ASM/Wt and BMI (Figure 1). The reference group consisted of those with lower BMIs in the highest ASM/Wt quartile. Men with lower BMIs in the lowest ASM/Wt quartile had a 2.83-fold higher risk of being in the highest quartile of IMT (95% CI, 1.15 to 6.96) than the reference group. Men with higher BMIs had significantly higher ORs for being in the highest quartile of IMT than the reference group, regardless of the ASM/Wt quartile (quartile [Q] 1: 4.05, Q2: 2.61, Q3: 4.64, Q4: 4.90). No association between ASM/Wt and the highest quartile of IMT was observed among women with lower BMIs. However, women with higher BMIs in the third ASM/Wt quartile had a 2.20-fold higher risk of being in the highest quartile of IMT (95% CI, 1.10 to 4.39) than the reference group.

DISCUSSION

The current study found that low skeletal muscle mass was independently associated with the highest quartile of IMT and carotid artery plaque in a cohort of middle-aged Korean men with lower BMIs, but not in those with higher BMIs. In women, there was no significant association of low skeletal muscle mass with the highest quartile of IMT or carotid artery plaque, regardless of BMI.

Several studies reporting inverse associations between the skeletal muscle mass and subclinical atherosclerosis have presumed that these phenomena may share a similar pathway and thus facilitate mutual abnormalities [12-15]. Moreover, several studies have examined the differential effects of various skeletal muscle mass and BMI categories on the risks of CVD or metabolic disorders [3-7], as skeletal muscle mass and obesity are not independent factors. One study reported that individuals with lower skeletal muscle mass and a lower BMI were at high risk [6], whereas others reported that those with lower skeletal muscle mass and a higher BMI were at high risk [3,4]. Still other studies found that individuals with lower skeletal muscle mass were at high risk for CVD or hypertension, regardless of BMI [5,7]. In contrast, some studies did not find any independent associations between skeletal muscle mass and subclinical atherosclerosis [16,17].

Although the mechanism underlying the potential association between low skeletal muscle mass and arterial wall thickening is unclear, both a decrease in skeletal muscle mass and an increase in arterial wall thickness may be age-related. Most previous studies about muscle mass, atherosclerosis, and CVD have mainly evaluated elderly populations [3,4,7,13,18,19]. Only a few studies have suggested that the inverse relationship between skeletal muscle mass and CVD risk was significant not only for elderly individuals, but also for middle-aged individuals [5,20]. In the current study, we also found an independent association between low skeletal muscle mass and arterial wall thickening in middle-aged non-obese men. To investigate whether there were different associations according to young and old age, we performed an additional analysis stratified by age subgroups (age ≤ 55 vs. >55 years). However, we were not able to examine the direct effect of age on the association between low skeletal muscle mass and arterial wall thickening (data not shown).

In this study, according to the stratified analysis (Table 2), the inverse association of skeletal muscle mass with arterial wall thickness was significant only in men with lower BMIs, but not in those with higher BMIs. In the combined analysis (Figure 1), we used a single reference group that consisted of non-obese men with the highest quartile of skeletal muscle mass. Non-obese men had a gradually higher risk of arterial wall thickening as skeletal muscle mass decreased compared with the reference group. However, obese men had a significantly higher risk of arterial wall thickening, regardless of skeletal muscle mass, compared with the reference group. Currently, the mechanisms underlying the differential relationship of skeletal muscle mass and arterial wall thickness according to BMI status remain unclear, although the presence of inflammatory markers might partially explain the observed outcomes. Previous animal and human studies have suggested associations of low-grade inflammation with low skeletal muscle mass [21], obesity [22], and atherosclerosis [23], although these relationships are not fully understood. In the current study, obese men regardless of skeletal muscle mass and non-obese men with low skeletal muscle mass had low-grade inflammation (data not shown), which may have affected arterial wall thickening. Previous studies have suggested that physical activity [24] and insulin resistance [18] might also exhibit differential relationships with skeletal muscle mass decline and arterial wall thickening according to obesity. To determine whether insulin resistance played a role in the association between low skeletal muscle mass and arterial wall thickening, we additionally adjusted for the insulin resistance index (data not shown); this caused the effect of low skeletal muscle mass to diminished to borderline in men with lower BMIs, suggesting that insulin resistance may partially but not fully explain the association between low appendicular skeletal muscle mass and arterial wall thickening.

As we mentioned, the significant relationship between low skeletal muscle mass and the highest quartile of IMT was not observed in women. Although the mechanism is unclear, there are some possible explanations. First, biological differences between genders might modify the effect of skeletal muscle mass on arterial wall stiffness or thickness. Age-related declines in skeletal muscle mass and muscle strength affect both genders, but are more prominent in men than in women [25]. Second, gender differences can also be attributed to gender-specific effects of sex hormones. In men, changes in skeletal muscle mass are controlled by testosterone levels, whereas women have much lower absolute degrees of decline in testosterone relative to men and therefore do not experience the effects of testosterone on skeletal muscle mass. Female sex hormones, especially estrogen, provide protective effects on cardiovascular function by directly modulating the reninangiotensin-aldosterone system [26,27]. Lastly, different lifestyle factors between genders, such as smoking status and alcohol intake, could affect the relationship between skeletal muscle mass and arterial wall thickness. In this aspect, women would likely be less affected by skeletal muscle mass declines than men. This finding is consistent with those of a few previous reports [12,15].

The current study also had some limitations of note. First, this study was cross-sectional in nature; therefore, the causal association between low muscle mass and arterial wall thickening is uncertain. Second, our estimation of skeletal muscle mass did not involve highly accurate modalities such as dual-energy X-ray absorptiometry (DEXA), computed tomography, or magnetic resonance imaging. However, BIA is a non-invasive method for assessing skeletal muscle mass that is useful in large populationbased studies. Previous studies have reported a good linear correlation of the BIA and DEXA methods for estimating skeletal muscle mass in healthy populations, regardless of gender, age, and race [28-30]. One such study of healthy men and women reported strong correlations of body composition parameters (correlation coefficients, 0.82 to 0.95) measured using BIA and DEXA [29]. However, a weakness of the BIA method is the potential effect of the participant's hydration status. Accordingly, we asked our participants to fast for at least 8 hours to reduce the possibility of measurement errors. Finally, BMI has limitations as an index of obesity, since it reflects not only fat mass, but also muscle mass.

In conclusion, we observed associations of low appendicular skeletal muscle mass with high IMT and carotid artery plaque in men with lower BMIs, but not in those with higher BMIs, even after adjusting for traditional cardiovascular risk factors. In women, there was no significant association of low appendicular skeletal muscle mass with high IMT and carotid artery plaque, regardless of BMI. Our findings suggest that the risk of atherosclerosis may be low in middle-aged Korean men with an appropriate body weight and skeletal muscle mass maintenance. Further prospective studies are needed to confirm that increasing skeletal muscle mass could decrease the risk of atherosclerosis in middle-aged Korean men with an appropriate body weight.

ACKNOWLEDGEMENTS

The study was supported by a grant (HI13C0715) from the Korea Health Technology R&D Project, funded by the Ministry of Health and Welfare, Republic of Korea.

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare for this study.

SUPPLEMENTARY MATERIALS

Supplementary Material 1: Table S1 is available at http://www.e-epih.org/.

Supplementary Material 2: Table S2 is available at http://www.e-epih.org/.

ORCID

Ji Eun Heo: https://orcid.org/0000-0001-6449-5856; Hyeon Chang Kim: https://orcid.org/0000-0001-7867-1240; Jee-Seon Shim: https://orcid.org/0000-0002-8671-3153; Bo Mi Song: https://orcid. org/0000-0003-3181-5803; Hye Yoon Bae: https://orcid.org/0000-0002-6058-1930; Ho Jae Lee: https://orcid.org/0000-0002-9649-7415; Il Suh: https://orcid.org/0000-0002-9689-7849

REFERENCES

- 1. Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin Geriatr Med 2011;27:337-339.
- Rolland Y, Czerwinski S, Abellan Van Kan G, Morley JE, Cesari M, Onder G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008;12:433-450.
- Chung JY, Kang HT, Lee DC, Lee HR, Lee YJ. Body composition and its association with cardiometabolic risk factors in the elderly: a focus on sarcopenic obesity. Arch Gerontol Geriatr 2013;56: 270-278.
- Atkins JL, Whincup PH, Morris RW, Lennon LT, Papacosta O, Wannamethee SG. Sarcopenic obesity and risk of cardiovascular disease and mortality: a population-based cohort study of older men. J Am Geriatr Soc 2014;62:253-260.
- Byeon CH, Kang KY, Kang SH, Bae EJ. Sarcopenia is associated with Framingham risk score in the Korean population: Korean National Health and Nutrition Examination Survey (KNHANES) 2010-2011. J Geriatr Cardiol 2015;12:366-372.
- Hwang YC, Cho IJ, Jeong IK, Ahn KJ, Chung HY. Differential association between sarcopenia and metabolic phenotype in Korean young and older adults with and without obesity. Obesity (Silver Spring) 2017;25:244-251.
- Chin SO, Rhee SY, Chon S, Hwang YC, Jeong IK, Oh S, et al. Sarcopenia is independently associated with cardiovascular disease in older Korean adults: the Korea National Health and Nutrition Examination Survey (KNHANES) from 2009. PLoS One 2013;8: e60119.
- 8. Kim TN, Park MS, Lim KI, Yang SJ, Yoo HJ, Kang HJ, et al. Skeletal muscle mass to visceral fat area ratio is associated with metabolic syndrome and arterial stiffness: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Res Clin Pract 2011;93:285-291.
- Shim JS, Song BM, Lee JH, Lee SW, Park JH, Choi DP, et al. Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) cohort: study protocol and results of the first 3 years of enrollment. Epidemiol Health 2017;39:e2017016.
- Furushima T, Miyachi M, Iemitsu M, Murakami H, Kawano H, Gando Y, et al. Comparison between clinical significance of heightadjusted and weight-adjusted appendicular skeletal muscle mass. J Physiol Anthropol 2017;36:15.
- Meng NH, Li CI, Liu CS, Lin CH, Lin WY, Chang CK, et al. Comparison of height- and weight-adjusted sarcopenia in a Taiwanese metropolitan older population. Geriatr Gerontol Int 2015;15:45-

53.

- Abbatecola AM, Chiodini P, Gallo C, Lakatta E, Sutton-Tyrrell K, Tylavsky FA, et al. Pulse wave velocity is associated with muscle mass decline: Health ABC study. Age (Dordr) 2012;34:469-478.
- 13. Campos AM, Moura FA, Santos SN, Freitas WM, Sposito AC; Brasilia Study on Healthy Aging and Brasilia Heart Study. Sarcopenia, but not excess weight or increased caloric intake, is associated with coronary subclinical atherosclerosis in the very elderly. Atherosclerosis 2017;258:138-144.
- Kato A, Ishida J, Endo Y, Takita T, Furuhashi M, Maruyama Y, et al. Association of abdominal visceral adiposity and thigh sarcopenia with changes of arteriosclerosis in haemodialysis patients. Nephrol Dial Transplant 2011;26:1967-1976.
- Ochi M, Kohara K, Tabara Y, Kido T, Uetani E, Ochi N, et al. Arterial stiffness is associated with low thigh muscle mass in middle-aged to elderly men. Atherosclerosis 2010;212:327-332.
- Jensky NE, Allison MA, Loomba R, Carnethon MR, de Boer IH, Budoff MJ, et al. Null association between abdominal muscle and calcified atherosclerosis in community-living persons without clinical cardiovascular disease: the multi-ethnic study of atherosclerosis. Metabolism 2013;62:1562-1569.
- Wassel CL, Laughlin GA, Saad SD, Araneta MR, Wooten W, Barrett-Connor E, et al. Associations of abdominal muscle area with 4-year change in coronary artery calcium differ by ethnicity among post-menopausal women. Ethn Dis 2015;25:435-442.
- Aubertin-Leheudre M, Lord C, Goulet ED, Khalil A, Dionne IJ. Effect of sarcopenia on cardiovascular disease risk factors in obese postmenopausal women. Obesity (Silver Spring) 2006;14:2277-2283.
- Soisson V, Brailly-Tabard S, Empana JP, Féart C, Ryan J, Bertrand M, et al. Low plasma testosterone and elevated carotid intimamedia thickness: importance of low-grade inflammation in elderly men. Atherosclerosis 2012;223:244-249.
- Kohara K, Ochi M, Tabara Y, Nagai T, Igase M, Miki T. Arterial stiffness in sarcopenic visceral obesity in the elderly: J-SHIPP study. Int J Cardiol 2012;158:146-148.
- 21. Balage M, Averous J, Rémond D, Bos C, Pujos-Guillot E, Papet I,

et al. Presence of low-grade inflammation impaired postprandial stimulation of muscle protein synthesis in old rats. J Nutr Biochem 2010;21:325-331.

- 22. Savetsky IL, Torrisi JS, Cuzzone DA, Ghanta S, Albano NJ, Gardenier JC, et al. Obesity increases inflammation and impairs lymphatic function in a mouse model of lymphedema. Am J Physiol Heart Circ Physiol 2014;307:H165-H172.
- 23. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009;6:399-409.
- Abe T, Thiebaud RS, Loenneke JP, Bemben MG, Loftin M, Fukunaga T. Influence of severe sarcopenia on cardiovascular risk factors in nonobese men. Metab Syndr Relat Disord 2012;10:407-412.
- 25. Dey DK, Bosaeus I, Lissner L, Steen B. Changes in body composition and its relation to muscle strength in 75-year-old men and women: a 5-year prospective follow-up study of the NORA cohort in Göteborg, Sweden. Nutrition 2009;25:613-619.
- Xue B, Johnson AK, Hay M. Sex differences in angiotensin IIand aldosterone-induced hypertension: the central protective effects of estrogen. Am J Physiol Regul Integr Comp Physiol 2013;305: R459-R463.
- 27. Sandberg K, Ji H. Sex differences in primary hypertension. Biol Sex Differ 2012;3:7.
- 28. Stewart SP, Bramley PN, Heighton R, Green JH, Horsman A, Losowsky MS, et al. Estimation of body composition from bioelectrical impedance of body segments: comparison with dual-energy X-ray absorptiometry. Br J Nutr 1993;69:645-655.
- 29. Boneva-Asiova Z, Boyanov MA. Body composition analysis by leg-to-leg bioelectrical impedance and dual-energy X-ray absorptiometry in non-obese and obese individuals. Diabetes Obes Metab 2008;10:1012-1018.
- 30. Malavolti M, Mussi C, Poli M, Fantuzzi AL, Salvioli G, Battistini N, et al. Cross-calibration of eight-polar bioelectrical impedance analysis versus dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21-82 years. Ann Hum Biol 2003;30:380-391.